Marijuana, endocannabinoids, and epilepsy: Potential and challenges for improved therapeutic intervention

Experimental Neurology

Volumn 244, Issue , 2013, Pages 43-50

  Hofmann, MacKenzie E ^a,b   Frazier, Charles J ^a,b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cannabinoids; CB1; Endocannabinoids; Epilepsy; Marijuana

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABIS; DRONABINOL; ENDOCANNABINOID; LIPID; METABOTROPIC RECEPTOR; PENTETRAZOLE; PHENOBARBITAL; PHENYTOIN;

CARBOXY TERMINAL SEQUENCE; DRUG MECHANISM; DRUG TARGETING; EPILEPSY; EPILEPTIC DISCHARGE; EPILEPTOGENESIS; GABAERGIC TRANSMISSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NERVE CELL EXCITABILITY; NERVE CELL PLASTICITY; NEUROLOGIC DISEASE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SEIZURE; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

ANIMALS; CANNABINOIDS; CANNABIS; CEREBRAL CORTEX; EPILEPSY; HUMANS; SIGNAL TRANSDUCTION;

EID: 84877598837     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.11.047     Document Type: Review

References (127)

1. Armstrong C., Morgan R.J., Soltesz I. Pursuing paradoxical proconvulsant prophylaxis for epileptogenesis. Epilepsia 2009, 50:1657-1669.
2. Bahremand A., Nasrabady S.E., Shafaroodi H., Ghasemi M., Dehpour A.R. Involvement of nitrergic system in the anticonvulsant effect of the cannabinoid CB(1) agonist ACEA in the pentylenetetrazole-induced seizure in mice. Epilepsy Res. 2009, 84:110-119.
3. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J. Ethnopharmacol. 2006, 105:1-25.
4. Ben-Ari Y., Cossart R. Kainate, a double agent that generates seizures: two decades of progress. Trends Neurosci. 2000, 23:580-587.
5. Berdyshev E.V. Cannabinoid receptors and the regulation of immune response. Chem. Phys. Lipids 2000, 108:169-190.
6. Bhaskaran M.D., Smith B.N. Cannabinoid-mediated inhibition of recurrent excitatory circuitry in the dentate gyrus in a mouse model of temporal lobe epilepsy. PLoS One 2010, 5:e10683.
7. Bhaskaran M.D., Smith B.N. Effects of TRPV1 activation on synaptic excitation in the dentate gyrus of a mouse model of temporal lobe epilepsy. Exp. Neurol. 2010, 223:529-536.
8. Blair R.E., Deshpande L.S., Sombati S., Falenski K.W., Martin B.R., DeLorenzo R.J. Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus. J. Pharmacol. Exp. Ther. 2006, 317:1072-1078.
9. Blair R.E., Deshpande L.S., Sombati S., Elphick M.R., Martin B.R., DeLorenzo R.J. Prolonged exposure to WIN55,212-2 causes downregulation of the CB1 receptor and the development of tolerance to its anticonvulsant effects in the hippocampal neuronal culture model of acquired epilepsy. Neuropharmacology 2009, 57:208-218.
10. Bodor A.L., Katona I., Nyiri G., Mackie K., Ledent C., Hajos N., Freund T.F. Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J. Neurosci. 2005, 25:6845-6856.
11. Braakman H.M., van Oostenbrugge R.J., van Kranen-Mastenbroek V.H., de Krom M.C. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy. Epilepsia 2009, 50:2171-2172.
12. Buckmaster P.S., Jongen-Relo A.L. Highly specific neuron loss preserves lateral inhibitory circuits in the dentate gyrus of kainate-induced epileptic rats. J. Neurosci. 1999, 19:9519-9529.
13. Carlson G., Wang Y., Alger B.E. Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat. Neurosci. 2002, 5:723-724.
14. Chen K., Baram T.Z., Soltesz I. Febrile seizures in the developing brain result in persistent modification of neuronal excitability in limbic circuits. Nat. Med. 1999, 5:888-894.
15. Chen K., Ratzliff A., Hilgenberg L., Gulyas A., Freund T.F., Smith M., Dinh T.P., Piomelli D., Mackie K., Soltesz I. Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures. Neuron 2003, 39:599-611.
16. Chen K., Neu A., Howard A.L., Foldy C., Echegoyen J., Hilgenberg L., Smith M., Mackie K., Soltesz I. Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures. J. Neurosci. 2007, 27:46-58.
17. Chevaleyre V., Castillo P.E. Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron 2003, 38:461-472.
18. Chevaleyre V., Castillo P.E. Endocannabinoid-mediated metaplasticity in the hippocampus. Neuron 2004, 43:871-881.
19. Chevaleyre V., Heifets B.D., Kaeser P.S., Sudhof T.C., Castillo P.E. Endocannabinoid-mediated long-term plasticity requires cAMP/PKA signaling and RIM1alpha. Neuron 2007, 54:801-812.
20. Chiu C.Q., Castillo P.E. Input-specific plasticity at excitatory synapses mediated by endocannabinoids in the dentate gyrus. Neuropharmacology 2008, 54:68-78.
21. Consroe P.F., Wood G.C., Buchsbaum H. Anticonvulsant nature of marihuana smoking. J. Am. Med. Assoc. 1975, 234:306-307.
22. Cortesi M., Fusar-Poli P. Potential therapeutical effects of cannabidiol in children with pharmacoresistant epilepsy. Med. Hypotheses 2007, 68:920-921.
23. Coull M.A., Johnston A.T., Pertwee R.G., Davies S.N. Action of delta-9-tetrahydrocannabinol on GABA(A) receptor-mediated responses in a grease-gap recording preparation of the rat hippocampal slice. Neuropharmacology 1997, 36:1387-1392.
24. Cunha J.M., Carlini E.A., Pereira A.E., Ramos O.L., Pimentel C., Gagliardi R., Sanvito W.L., Lander N., Mechoulam R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980, 21:175-185.
25. Deshpande L.S., Blair R.E., Ziobro J.M., Sombati S., Martin B.R., DeLorenzo R.J. Endocannabinoids block status epilepticus in cultured hippocampal neurons. Eur. J. Pharmacol. 2007, 558:52-59.
26. Deshpande L.S., Sombati S., Blair R.E., Carter D.S., Martin B.R., DeLorenzo R.J. Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy. Neurosci. Lett. 2007, 411:11-16.
27. Deutsch D.G., Ueda N., Yamamoto S. The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot. Essent. Fatty Acids 2002, 66:201-210.
28. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994, 372:686-691.
29. Di S., Malcher-Lopes R., Halmos K.C., Tasker J.G. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J. Neurosci. 2003, 23:4850-4857.
30. Di S., Boudaba C., Popescu I.R., Weng F.J., Harris C., Marcheselli V.L., Bazan N.G., Tasker J.G. Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. J. Physiol. 2005, 569:751-760.
31. Di S., Malcher-Lopes R., Marcheselli V.L., Bazan N.G., Tasker J.G. Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 2005, 146:4292-4301.
32. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10819-10824.
33. Domenici M.R., Azad S.C., Marsicano G., Schierloh A., Wotjak C.T., Dodt H.U., Zieglgansberger W., Lutz B., Rammes G. Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J. Neurosci. 2006, 26:5794-5799.
34. Dudek F.E., Pouliot W.A., Rossi C.A., Staley K.J. The effect of the cannabinoid-receptor antagonist, SR141716, on the early stage of kainate-induced epileptogenesis in the adult rat. Epilepsia 2010, 51(Suppl 3):126-130.
35. Echegoyen J., Armstrong C., Morgan R.J., Soltesz I. Single application of a CB1 receptor antagonist rapidly following head injury prevents long-term hyperexcitability in a rat model. Epilepsy Res. 2009, 85:123-127.
36. Edwards D.A., Zhang L., Alger B.E. Metaplastic control of the endocannabinoid system at inhibitory synapses in hippocampus. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:8142-8147.
37. Ellison J.M., Gelwan E., Ogletree J. Complex partial seizure symptoms affected by marijuana abuse. J. Clin. Psychiatry 1990, 51:439-440.
38. Engler B., Freiman I., Urbanski M., Szabo B. Effects of exogenous and endogenous cannabinoids on GABAergic neurotransmission between the caudate-putamen and the globus pallidus in the mouse. J. Pharmacol. Exp. Ther. 2006, 316:608-617.
39. Falenski K.W., Blair R.E., Sim-Selley L.J., Martin B.R., DeLorenzo R.J. Status epilepticus causes a long-lasting redistribution of hippocampal cannabinoid type 1 receptor expression and function in the rat pilocarpine model of acquired epilepsy. Neuroscience 2007, 146:1232-1244.
40. Falenski K.W., Carter D.S., Harrison A.J., Martin B.R., Blair R.E., DeLorenzo R.J. Temporal characterization of changes in hippocampal cannabinoid CB(1) receptor expression following pilocarpine-induced status epilepticus. Brain Res. 2009, 1262:64-72.
41. Fortin D.A., Trettel J., Levine E.S. Brief trains of action potentials enhance pyramidal neuron excitability via endocannabinoid-mediated suppression of inhibition. J. Neurophysiol. 2004, 92:2105-2112.
42. Fukudome Y., Ohno-Shosaku T., Matsui M., Omori Y., Fukaya M., Tsubokawa H., Taketo M.M., Watanabe M., Manabe T., Kano M. Two distinct classes of muscarinic action on hippocampal inhibitory synapses: M2-mediated direct suppression and M1/M3-mediated indirect suppression through endocannabinoid signalling. Eur. J. Neurosci. 2004, 19:2682-2692.
43. Gao Y., Vasilyev D.V., Goncalves M.B., Howell F.V., Hobbs C., Reisenberg M., Shen R., Zhang M.Y., Strassle B.W., Lu P., Mark L., Piesla M.J., Deng K., Kouranova E.V., Ring R.H., Whiteside G.T., Bates B., Walsh F.S., Williams G., Pangalos M.N., Samad T.A., Doherty P. Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J. Neurosci. Off J Soc Neurosci. 2010, 30:2017-2024.
44. Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 1964, 86:1646-1647.
45. Gholizadeh S., Shafaroodi H., Ghasemi M., Bahremand A., Sharifzadeh M., Dehpour A.R. Ultra-low dose cannabinoid antagonist AM251 enhances cannabinoid anticonvulsant effects in the pentylenetetrazole-induced seizure in mice. Neuropharmacology 2007, 53:763-770.
46. Gordon E., Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001, 42:1266-1272.
47. Gross D.W., Hamm J., Ashworth N.L., Quigley D. Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center. Neurology 2004, 62:2095-2097.
48. Hajos N., Katona I., Naiem S.S., Mackie K., Ledent C., Mody I., Freund T.F. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur. J. Neurosci 2000, 12:3239-3249.
49. Hampson R.E., Evans G.J., Mu J., Zhuang S.Y., King V.C., Childers S.R., Deadwyler S.A. Role of cyclic AMP dependent protein kinase in cannabinoid receptor modulation of potassium "A-current" in cultured rat hippocampal neurons. Life Sci. 1995, 56:2081-2088.
50. Hashimotodani Y., Ohno-Shosaku T., Tsubokawa H., Ogata H., Emoto K., Maejima T., Araishi K., Shin H.S., Kano M. Phospholipase Cbeta serves as a coincidence detector through its Ca2+ dependency for triggering retrograde endocannabinoid signal. Neuron 2005, 45:257-268.
51. Hazekamp A., Grotenhermen F. Review on clinical studies with cannabis and cannabinoids 2005-2009. Cannabinoids 2010, 5:1-21.
52. Heifets B.D., Chevaleyre V., Castillo P.E. Interneuron activity controls endocannabinoid-mediated presynaptic plasticity through calcineurin. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10250-10255.
53. Hillard C.J., Edgemond W.S., Jarrahian A., Campbell W.B. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem. 1997, 69:631-638.
54. Hofmann M.E., Nahir B., Frazier C.J. Endocannabinoid-mediated depolarization-induced suppression of inhibition in hilar mossy cells of the rat dentate gyrus. J. Neurophysiol. 2006, 96:2501-2512.
55. Hofmann M.E., Nahir B., Frazier C.J. Excitatory afferents to CA3 pyramidal cells display differential sensitivity to CB1 dependent inhibition of synaptic transmission. Neuropharmacology 2008, 55:1140-1146.
56. Hofmann M.E., Bhatia C., Frazier C.J. Cannabinoid receptor agonists potentiate action potential-independent release of GABA in the dentate gyrus through a CB1 receptor-independent mechanism. J. Physiol. 2011, 589:3801-3821.
57. Howard A.L., Neu A., Morgan R.J., Echegoyen J.C., Soltesz I. Opposing modifications in intrinsic currents and synaptic inputs in post-traumatic mossy cells: evidence for single-cell homeostasis in a hyperexcitable network. J. Neurophysiol. 2007, 97:2394-2409.
58. Isokawa M., Alger B.E. Retrograde endocannabinoid regulation of GABAergic inhibition in the rat dentate gyrus granule cell. J. Physiol. 2005, 567:1001-1010.
59. Jo Y.H., Chen Y.J., Chua S.C., Talmage D.A., Role L.W. Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron 2005, 48:1055-1066.
60. Jones N.A., Hill A.J., Smith I., Bevan S.A., Williams C.M., Whalley B.J., Stephens G.J. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J. Pharmacol. Exp. Ther. 2010, 332:569-577.
61. Kano M., Ohno-Shosaku T., Hashimotodani Y., Uchigashima M., Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev. 2009, 89:309-380.
62. Katona I., Urban G.M., Wallace M., Ledent C., Jung K.M., Piomelli D., Mackie K., Freund T.F. Molecular composition of the endocannabinoid system at glutamatergic synapses. J. Neurosci. 2006, 26:5628-5637.
63. Keeler M.H., Reifler C.B. Grand mal convulsions subsequent to marijuana use. Case report. Dis. Nerv. Syst. 1967, 28:474-475.
64. Khaspekov L.G., Brenz Verca M.S., Frumkina L.E., Hermann H., Marsicano G., Lutz B. Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur. J. Neurosci. 2004, 19:1691-1698.
65. Kreitzer A.C., Regehr W.G. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 2001, 29:717-727.
66. Kreitzer A.C., Regehr W.G. Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J. Neurosci. 2001, 21:RC174.
67. Kreitzer F.R., Stella N. The therapeutic potential of novel cannabinoid receptors. Pharmacol. Ther. 2009, 122:83-96.
68. Llano I., Leresche N., Marty A. Calcium entry increases the sensitivity of cerebellar Purkinje cells to applied GABA and decreases inhibitory synaptic currents. Neuron 1991, 6:565-574.
69. Lovinger D.M. Presynaptic modulation by endocannabinoids. Handb. Exp. Pharmacol. 2008, 435-477.
70. Ludanyi A., Eross L., Czirjak S., Vajda J., Halasz P., Watanabe M., Palkovits M., Magloczky Z., Freund T.F., Katona I. Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus. J. Neurosci. 2008, 28:2976-2990.
71. Lutz B., Monory K. Soothing the seizures of children. Nat. Med. 2008, 14:721-722.
72. Mackie K., Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J. 2006, 8:E298-E306.
73. Mackie K., Lai Y., Westenbroek R., Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in Att20 cells transfected with rat-brain cannabinoid receptor. J. Neurosci. 1995, 15:6552-6561.
74. Magloczky Z., Toth K., Karlocai R., Nagy S., Eross L., Czirjak S., Vajda J., Rasonyi G., Kelemen A., Juhos V., Halasz P., Mackie K., Freund T.F. Dynamic changes of CB1-receptor expression in hippocampi of epileptic mice and humans. Epilepsia 2010, 51(Suppl 3):115-120.
75. Maneuf Y.P., Nash J.E., Crossman A.R., Brotchie J.M. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur. J. Pharmacol. 1996, 308:161-164.
76. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutierrez S.O., Van der Stelt M., Lopez-Rodriguez M.L., Casanova E., Schutz G., Zieglgansberger W., Di Marzo V., Behl C., Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003, 302:84-88.
77. Melis M., Perra S., Muntoni A.L., Pillolla G., Lutz B., Marsicano G., Di Marzo V., Gessa G.L., Pistis M. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J. Neurosci. 2004, 24:10707-10715.
78. Melis M., Pistis M., Perra S., Muntoni A.L., Pillolla G., Gessa G.L. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J. Neurosci. 2004, 24:53-62.
79. Monory K., Massa F., Egertova M., Eder M., Blaudzun H., Westenbroek R., Kelsch W., Jacob W., Marsch R., Ekker M., Long J., Rubenstein J.L., Goebbels S., Nave K.A., During M., Klugmann M., Wolfel B., Dodt H.U., Zieglgansberger W., Wotjak C.T., Mackie K., Elphick M.R., Marsicano G., Lutz B. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 2006, 51:455-466.
80. Moriconi A., Cerbara I., Maccarrone M., Topai A. GPR55: current knowledge and future perspectives of a purported "type-3" cannabinoid receptor. Curr. Med. Chem. 2010, 17:1411-1429.
81. Mukhtarov M., Ragozzino D., Bregestovski P. Dual Ca2+ modulation of glycinergic synaptic currents in rodent hypoglossal motoneurones. J. Physiol. 2005, 569:817-831.
82. Nahir B., Lindsly C., Frazier C.J. mGluR-mediated and endocannabinoid-dependent long-term depression in the hilar region of the rat dentate gyrus. Neuropharmacology 2010, 58(4-5):712-721.
83. Narushima M., Uchigashima M., Hashimoto K., Watanabe M., Kano M. Depolarization-induced suppression of inhibition mediated by endocannabinoids at synapses from fast-spiking interneurons to medium spiny neurons in the striatum. Eur. J. Neurosci. 2006, 24:2246-2252.
84. Ng S.K., Brust J.C., Hauser W.A., Susser M. Illicit drug use and the risk of new-onset seizures. Am. J. Epidemiol. 1990, 132:47-57.
85. Niehaus J.L., Liu Y., Wallis K.T., Egertova M., Bhartur S.G., Mukhopadhyay S., Shi S., He H., Selley D.E., Howlett A.C., Elphick M.R., Lewis D.L. CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a. Mol. Pharmacol. 2007, 72:1557-1566.
86. Nyiri G., Szabadits E., Cserep C., Mackie K., Shigemoto R., Freund T.F. GABAB and CB1 cannabinoid receptor expression identifies two types of septal cholinergic neurons. Eur. J. Neurosci. 2005, 21:3034-3042.
87. Ohno-Shosaku T., Maejima T., Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001, 29:729-738.
88. Ohno-Shosaku T., Tsubokawa H., Mizushima I., Yoneda N., Zimmer A., Kano M. Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J. Neurosci. 2002, 22:3864-3872.
89. Ohno-Shosaku T., Matsui M., Fukudome Y., Shosaku J., Tsubokawa H., Taketo M.M., Manabe T., Kano M. Postsynaptic M1 and M3 receptors are responsible for the muscarinic enhancement of retrograde endocannabinoid signalling in the hippocampus. Eur. J. Neurosci. 2003, 18:109-116.
90. Okamoto Y., Wang J., Morishita J., Ueda N. Biosynthetic pathways of the endocannabinoid anandamide. Chem. Biodivers. 2007, 4:1842-1857.
91. Pertwee R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 2009, 156:397-411.
92. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci 2003, 4:873-884.
93. Piomelli D., Beltramo M., Glasnapp S., Lin S.Y., Goutopoulos A., Xie X.Q., Makriyannis A. Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:5802-5807.
94. Pitler T.A., Alger B.E. Postsynaptic spike firing reduces synaptic GABAA responses in hippocampal pyramidal cells. J. Neurosci. 1992, 12:4122-4132.
95. Radwan M.M., Elsohly M.A., Slade D., Ahmed S.A., Khan I.A., Ross S.A. Biologically active cannabinoids from high-potency Cannabis sativa. J. Nat. Prod. 2009, 72:906-911.
96. Ratzliff A.H., Santhakumar V., Howard A., Soltesz I. Mossy cells in epilepsy: rigor mortis or vigor mortis?. Trends Neurosci. 2002, 25:140-144.
97. Reich C.G., Karson M.A., Karnup S.V., Jones L.M., Alger B.E. Regulation of IPSP theta rhythm by muscarinic receptors and endocannabinoids in hippocampus. J. Neurophysiol. 2005, 94(6):4290-4299.
98. Romigi A., Bari M., Placidi F., Marciani M.G., Malaponti M., Torelli F., Izzi F., Prosperetti C., Zannino S., Corte F., Chiaramonte C., Maccarrone M. Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy. Epilepsia 2010, 51:768-772.
99. Ross R.A. Allosterism and cannabinoid CB(1) receptors: the shape of things to come. Trends Pharmacol. Sci. 2007, 28:567-572.
100. Ross R.A. The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci. 2009, 30:156-163.
101. Ryberg E., Larsson N., Sjogren S., Hjorth S., Hermansson N.O., Leonova J., Elebring T., Nilsson K., Drmota T., Greasley P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 2007, 152:1092-1101.
102. Sang N., Zhang J., Chen C. Anandamide potentiation of miniature spontaneous excitatory synaptic transmission is mediated via IP3 pathway. Neurochem. Int. 2010, 56:590-596.
103. Schweitzer P. Cannabinoids decrease the K(+) M-current in hippocampal CA1 neurons. J. Neurosci. 2000, 20:51-58.
104. Shafaroodi H., Samini M., Moezi L., Homayoun H., Sadeghipour H., Tavakoli S., Hajrasouliha A.R., Dehpour A.R. The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice. Neuropharmacology 2004, 47:390-400.
105. Sloviter R.S., Zappone C.A., Harvey B.D., Bumanglag A.V., Bender R.A., Frotscher M. "Dormant basket cell" hypothesis revisited: relative vulnerabilities of dentate gyrus mossy cells and inhibitory interneurons after hippocampal status epilepticus in the rat. J. Comp. Neurol. 2003, 459:44-76.
106. Steffens M., Schulze-Bonhage A., Surges R., Feuerstein T.J. Fatty acid amidohydrolase in human neocortex-activity in epileptic and non-epileptic brain tissue and inhibition by putative endocannabinoids. Neurosci. Lett. 2005, 385:13-17.
107. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997, 388:773-778.
108. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 1995, 215:89-97.
109. Sugiura T., Kishimoto S., Oka S., Gokoh M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog. Lipid Res. 2006, 45:405-446.
110. Sugiura T., Oka S., Ikeda S., Waku K., Onaivi E.S., Di Marzo V. Occurrence, biosynthesis, and metabolism of endocannabinoids. Endocannabinoids 2006, 177-214. CRC Press.
111. Tanimura A., Yamazaki M., Hashimotodani Y., Uchigashima M., Kawata S., Abe M., Kita Y., Hashimoto K., Shimizu T., Watanabe M., Sakimura K., Kano M. The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron 2010, 65:320-327.
112. Trettel J., Levine E.S. Endocannabinoids mediate rapid retrograde signaling at interneuron right-arrow pyramidal neuron synapses of the neocortex. J. Neurophysiol. 2003, 89:2334-2338.
113. Turner C.E., Elsohly M.A., Boeren E.G. Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J. Nat. Prod. 1980, 43:169-234.
114. Twitchell W., Brown S., Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol. 1997, 78:43-50.
115. Wallace M.J., Wiley J.L., Martin B.R., DeLorenzo R.J. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur. J. Pharmacol. 2001, 428:51-57.
116. Wallace M.J., Martin B.R., DeLorenzo R.J. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur. J. Pharmacol. 2002, 452:295-301.
117. Wallace M.J., Blair R.E., Falenski K.W., Martin B.R., Delorenzo R.J. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 2003, 307:129-137.
118. Wallmichrath I., Szabo B. Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse. Neuroscience 2002, 113:671-682.
119. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001, 410:588-592.
120. Wyeth M.S., Zhang N., Mody I., Houser C.R. Selective reduction of cholecystokinin-positive basket cell innervation in a model of temporal lobe epilepsy. J. Neurosci. Off J. Soc. Neurosci. 2010, 30:8993-9006.
121. Xi Z.X., Peng X.Q., Li X., Song R., Zhang H.Y., Liu Q.R., Yang H.J., Bi G.H., Li J., Gardner E.L. Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice. Nat. Neurosci. 2011, 14:1160-1166.
122. Yates M.L., Barker E.L. Inactivation and biotransformation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol. Mol. Pharmacol. 2009, 76:11-17.
123. Yin H., Chu A., Li W., Wang B., Shelton F., Otero F., Nguyen D.G., Caldwell J.S., Chen Y.A. Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J. Biol. Chem. 2009, 284:12328-12338.
124. Yoshida T., Hashimoto K., Zimmer A., Maejima T., Araishi K., Kano M. The cannabinoid CB1 receptor mediates retrograde signals for depolarization-induced suppression of inhibition in cerebellar Purkinje cells. J. Neurosci. 2002, 22:1690-1697.
125. Yoshino H., Miyamae T., Hansen G., Zambrowicz B., Flynn M., Pedicord D., Blat Y., Westphal R.S., Zaczek R., Lewis D.A., Gonzalez-Burgos G. Postsynaptic diacylglycerol lipase alpha mediates retrograde endocannabinoid suppression of inhibition in mouse prefrontal cortex. J. Physiol. 2011, 589:4857-4884.
126. Zagnoni P.G., Albano C. Psychostimulants and epilepsy. Epilepsia 2002, 43(Suppl 2):28-31.
127. Zhu P.J., Lovinger D.M. Retrograde endocannabinoid signaling in a postsynaptic neuron/synaptic bouton preparation from basolateral amygdala. J. Neurosci. 2005, 25:6199-6207.